Norma Solis, MD
Family Medicine · Reedley, CANPI 1790791622
Payments from drug & device makers
Across 328 payments — averaging $17.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$2K
- AstraZeneca$788
- Pfizer$615
- Lilly USA, LLC$468
- GSK$392
- Ultragenyx Pharmaceutical Inc.$206
- plus $2K from 28 others
What the payments were for
- Food & beverage$5,631100%
- Education$60%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 117 | $1,592 |
| AstraZeneca(2 entities) | 43 | $788 |
| Pfizer | 39 | $615 |
| Lilly USA, LLC | 27 | $468 |
| GSK | 16 | $392 |
| Ultragenyx Pharmaceutical Inc. | 11 | $206 |
| Merck | 10 | $203 |
| Jazz Pharmaceuticals Inc. | 2 | $186 |
| Boehringer Ingelheim | 9 | $144 |
| Sanofi Pasteur Inc. | 5 | $112 |
| Biohaven Pharmaceutical Holding Company Ltd. | 6 | $108 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $85 |
| Biohaven Pharmaceuticals, Inc. | 3 | $79 |
| Abbott | 4 | $77 |
| Astellas Pharma US Inc | 3 | $57 |
| AbbVie(2 entities) | 3 | $53 |
| Ironwood Pharmaceuticals, Inc | 3 | $52 |
| Phathom Pharmaceuticals, Inc. | 3 | $48 |
| Amarin Pharma, Inc. | 2 | $42 |
| Dexcom, Inc. | 2 | $38 |
| Philips North America LLC | 2 | $37 |
| Mannkind Corporation | 2 | $32 |
| Regeneron Healthcare Solutions, Inc. | 1 | $25 |
| Kyowa Kirin, Inc. | 1 | $22 |
| Seqirus USA Inc | 1 | $22 |
| Phadia US Inc. | 1 | $20 |
| Ipsen Biopharmaceuticals, Inc | 1 | $19 |
| Otsuka America Pharmaceutical, Inc. | 1 | $19 |
| Exact Sciences | 1 | $18 |
| Medtronic | 1 | $18 |
| Dynavax Technologies Corporation | 1 | $16 |
| Genentech USA, Inc. | 1 | $15 |
| Kowa Pharmaceuticals America, Inc. | 1 | $15 |
| Bayer | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TRELEGY ELLIPTA$125
- XYWAV$122
- Ozempic$116
How this compares
$5,637 in reported general payments places this provider in the 90th percentile of 10,533 family medicine providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 85 | $102,500 |
| OzempicSemaglutide | 74 | $100,325 |
| EliquisApixaban | 83 | $62,285 |
| JanuviaSitagliptin Phosphate | 15 | $21,212 |
| MyrbetriqMirabegron | 15 | $19,804 |
| Tresiba Flextouch U-200Insulin Degludec | 22 | $18,233 |
| Tresiba Flextouch U-100Insulin Degludec | 14 | $10,006 |
| FarxigaDapagliflozin Propanediol | 11 | $8,682 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 17 | $7,945 |
| Repatha SureclickEvolocumab | 13 | $7,179 |
| TradjentaLinagliptin | 11 | $7,118 |
| Atorvastatin Calcium | 511 | $6,687 |
| Esomeprazole Magnesium | 16 | $6,474 |
| Levothyroxine Sodium | 406 | $5,400 |
| Dexlansoprazole DrDexlansoprazole | 11 | $5,183 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Tradjenta | $144 | $109,61896 claims |
| Novo NordiskOzempic | $1,592 | $100,32574 claims |
| PfizerEliquis | $615 | $62,28583 claims |
| MerckJanuvia | $203 | $21,21215 claims |
| Astellas Pharma US IncMyrbetriq | $57 | $19,80415 claims |
| AstraZenecaFarxiga | $788 | $8,68211 claims |
| GSKAnoro Ellipta | $392 | $7,94517 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 10,533 family medicine providers in California.
Other family medicine in Reedley
- Amina HaggagNorthridge$112.8M
- Steven ReynoldsLong Beach$53M
- Rizwana MohseniLake Forest$26.7M
- Daniel JohnsonSan Diego$15.7M
- Stacey LayleSan Diego$14.8M
- Apinya VutikullirdCypress$14.3M
- Hanid AudishSpring Valley$13.6M
- Augusto FocilOxnard$12.6M
- Jack VuLong Beach$10.1M
- Suzanne FussellOxnard$8.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.